The University of Chicago Comprehensive Cancer Center (UCCCC) is led by a Strong Leadership Team, which effectively represents all components of the academic units Involved In cancer research and clinical care, and tightly links the basic, clinical, translational and population research programs. The Senior Leaders includes 2 Co-Deputy Directors and 7 Associate Directors. Over the past 5 years, strategic changes In the leadership have facilitated the development of an Integrated and shared vision for the cancer programs. New appointments, together with considerable continuity of leadership, have enhanced organizational and planning capabilities. Richard Schilsky, MD (Chief, Section of Hematology/ Oncology) replaced Dr. Vokes (who was appointed Chair of Medicine) as Co-Deputy Director for Clinical Sciences. He works closely with Marsha Rosner, PhD (Chair, Ben May Department for Cancer Research) who remains as the Co-Deputy Director for Basic Sciences. The Associate Directors for Basic Sciences (Geoffrey Greene, PhD, Vice Chair of the Ben May Department for Cancer Research), Clinical Sciences (Mark Ratain, MD, Professor of Medicine, Director, Center for Personalized Therapeutics), and Population Research (Habibul Ahsan, MBBS, MMedSc, Professor of Health Studies, Director, Center for Cancer EpWemiology and Prevention), all recognized as leaders in their fields, continue in their roles. Marcy List, PhD, continues in her role as Associate Director for Administration. James Schilling, PhD, an experienced investigator with expertise in proteomics, now serves as the Associate Director for Core Facilities, and Executive Director of the BSD Office of Shared Research Facilities. In 2011, the UCCCC created two new positions, the Associate Director for Translational Sciences (Ravi Salgia, MD, PhD, Professor of Medicine, Vice Chair for Translational Research, Dept. of Medicine) and the Associate Director for Education (Ezra Cohen, MD, Associate Professor of Medicine, Director of the Hematology/Oncology Fellowship Program). The above individuals are members (with the exception of the Associate Director for Core Facilities) of the UCCCC Executive Committee (EC) and the Cancer Advisory Committee (CAC). The CAC also includes additional leaders of academic units engaged In cancer research and care of patients with cancer, e.g.. Radiation Oncology, Surgical Oncology, Urology and Pediatric Hematology/Oncology. The Deputy Directors and Associate Directors, work closely with the Director, and are responsible for strategic planning, general administration of the UCCCC and Implementation of specific programs within their areas. Together they are responsible for identifying and implementing interdisciplinary efforts, identifying recruitment needs, leading recruitment searches, prioritizing allocation of UCCCC resources (including final decisions about the Pilot Project awards), developing new shared resources, and worthing with the Program Leaders In advancing programmatic goals. Over the past year, this group has taken primary responsibility for developing the UCCCC Strategic Plan.

Public Health Relevance

Advancing the UCCCC's mission, to elucidate the determinants of cancer, to develop cures for cancer, and to prevent cancer, requires a strategic vision and an emphasis on translational and interdisciplinary research The Senior Leadership Team is responsible for developing this vision, and creating the environment and Infrastructure necessary for collaboration among a diverse and dedicated team of outstanding basic, clinical, translational, and population researchers, and trainees.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
United States
Zip Code
Feng, Christine H; Gerry, Emily; Chmura, Steven J et al. (2015) An image-guided study of setup reproducibility of postmastectomy breast cancer patients treated with inverse-planned intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 91:58-64
Ming, Mei; Zhao, Baozhong; Shea, Christopher R et al. (2015) Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. J Allergy Clin Immunol 135:936-45.e4
Ming, Mei; Zhao, Baozhong; Qiang, Lei et al. (2015) Effect of immunosuppressants tacrolimus and mycophenolate mofetil on the keratinocyte UVB response. Photochem Photobiol 91:242-7
Shah, Palak; He, Yu-Ying (2015) Molecular regulation of UV-induced DNA repair. Photochem Photobiol 91:254-64
Ming, Mei; Han, Weinong; Zhao, Baozhong et al. (2014) SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer. Cancer Res 74:5925-33
Ramírez, Jacqueline; Kim, Tae Won; Liu, Wanqing et al. (2014) A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics 24:129-32
Rudra, Sonali; Al-Hallaq, Hania A; Feng, Christine et al. (2014) Effect of RTOG breast/chest wall guidelines on dose-volume histogram parameters. J Appl Clin Med Phys 15:4547
Weng, Liming; Ziliak, Dana; Lacroix, Bonnie et al. (2014) Integrative "omic" analysis for tamoxifen sensitivity through cell based models. PLoS One 9:e93420
Stumpf, Melanie; Zhou, Xuyu; Chikuma, Shunsuke et al. (2014) Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. Eur J Immunol 44:1737-46
Geeleher, Paul; Cox, Nancy J; Huang, R Stephanie (2014) Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 15:R47

Showing the most recent 10 out of 354 publications